NCT02040831View on ClinicalTrials.gov

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV LID ΔM2-2 Vaccine

10\^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

BIOLOGICAL

Placebo Vaccine

0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)

Trial Locations (1)

21205

Center for Immunization Research, JHU, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02040831 - Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter